Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2008 / N 2

Фармакодинамика и нежелательные эффекты ингаляционных бета-2-агонистов (Список литературы)
Н.Б. Лазарева, А.И. Карлов, А.Г. Абросимов, В.В. Архипов


1. Johnson M. The beta-adrenoceptor.Am J Respir Crit Care Med. 1998 Nov;158 (5 Pt 3):S146-53.
2. Strader C. D. et al. J. Biol. Chem. 1989; 264:13572–13580.
3. Lima JJ, Thomason DB, Mohamed MH, Eberle LV, Self TH, Johnson JA. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther. 1999 May;65 (5):519-25.
4. Israel E et.al. The Effect of Polymorphisms of the b2-Adrenergic Receptor on the Response to Regular Use of Albuterol in Asthma. Am J Respir Crit Care Med Vol 162. pp 75–80, 2000.
5. Israel E, Chinchilli VM, Ford JG et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. The Lancet 2004; 364:1505-1512
6. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term b agonist use: influence of b2 adrenoceptor polymorphism. Thorax 2000;55:762-7.
7. Wechsler ME et al. Beta-Adrenergic Receptor Polymorphisms and Response to Salmeterol. Am J Respir Crit Care Med Vol 173. pp 519–526, 2006
8. Palmer CNA, Lipworth BJ, Lee S et al. Arginine-16 ß2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 2006;61:940-944
9. McGraw DW, Liggett SB. Molecular mechanisms of beta2-adrenergic receptor function and regulation.Proc Am Thorac Soc. 2005;2 (4):292-6;
10. Van Veen A, Weller FR, Wierenga EA et. al. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists.
11. Tan KS, Grove A, McLean A, Gnosspelius Y, Hall IP, Lipworth BJ. Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med. 1997 Jul;156 (1):28-35.
12. Lee DKC, Jackson CN, Bates CE & Lipworth BJ. Cross tolerance to salbutamol occurs independently of b2-adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol. Thorax 2004;59:662–667.
13. Kuna P, Peters MJ, Buhl R. Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone. Abstract presented at the ERS Congress 2006.
14. E.R. Bleecker, D.S. Postma, R. Lawrance, D.A. Meyers, H. Ambrose, M. Goldman. Effect of Polymorphisms in the Beta2-Adrenergic Receptor Gene (ADRB2) on Response to Long-Acting Beta2-Agonist (LABA) Therapy. The Journal of Allergy and Clinical Immunology February 2007 (Vol. 119, Issue 2, Pages 524-525)
15. Lipworth BJ, Clark RA, Fraser CG, et al. The biochemical effects of high-dose inhaled salbutamol in patients with asthma. Eur J Clin Pharmacol 1989;36:357–60.
16. Newhouse MT, Chapman KR, McCallum AL, et al. Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. Chest 1996; 110: 595­603
17. Lipworth BJ. Revisiting interactions between hypoxaemia and beta2-agonists in asthma. Thorax 2001;56:506–507
18. Au DH, Lemaitre RN, Curtis JR, Smith NL, Psaty BM. The risk of myocardial infarction associated with inhaled b-adrenoceptor agonists. Am J Respir Crit Care Med 2000;161:827–830.
19. Au DH, Curtis JR, Every NR et al. Association Between Inhaled @b-Agonists and the Risk of Unstable Angina and Myocardial Infarction. CHEST 2002; 121:846–851
20. Källström B-L, Sjöberg J, Waldeck B. The interaction between salmeterol and @b2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro. Br J Pharmacol 1994; 113: 687–692.
21. Scola A-M, Chong LK, Suvarna K. et al. British Journal of Pharmacology (2004) 141, 163–171
22. Hanania NA et al. Am J Respir Crit Care Med Vol 165. pp 1353–1358, 2002
23. Ramage L, Lipworth BJ, Ingram CG, Cree LA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994;88:262–368.
24. Nelson JA, Strauss L, Skowronski M, Ciufo R, Novak R, McFadden ER. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 1998;339:141–146.
25. Giannini D, Carletti A, Dente FL, Bacci E, Di Franco A, Vagaggini B, Paggiaro PL. Tolerance to the protective effect of salmeterol on allergen challenge. Chest 1996;110:1452–1457.
26. Cheung D, Timmers MC, Zwinderman AH, Bel EH, Dijkman JH, Sterk PJ. Long-term effects of a long-acting 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992;327:1198–1203.
27. Kenakin TP. Competitive antagonism. In: Kenakin TP, ed. Pharmacologic analysis of drug- receptor interaction. 2nd ed. New York, Raven Press, 1993: pp. 278–322.
28. Barnes PJ. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995; 152: 838–860.
29. Rabe KF, Giembycz MA, Dent G. Salmeterol is a competitive antagonist at в-adrenoceptor mediating inhibition of respiratory burst in guinea-pig eosinophils. Eur J Pharmacol 1993; 231: 305–308.
30. M. Molimard, E. Naline, Y. Zhang. Long- and short-acting в2 adrenoceptor agonists: interactions inhuman contracted bronchi Eur Respir J 1998; 11: 583–588
31. A van Veen, FR Weller, EA Wierenga. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists. Pulm Pharmacol Ther, January 1, 2003; 16 (3): 153-61.
32. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129: 15-26
33. Gillissen A, Lecheler J. Corticophobia in asthma. Med Klin (Munich). 2003 Aug 15;98 (8):417-22
34. Poluzzi E, Resi D, Zuccheri P, Motola D, De Ponti F, Vaccheri A, Montanaro N. Use of anti-asthmatic drugs in Italy: analysis of prescriptions in general practice in the light of guidelines for asthma treatment. Eur J Clin Pharmacol. 2002 Apr;58 (1):55-9. Epub 2002 Feb 20.
35. Barnes PJ, Pedersen S, Busse WW. Efficacy and Safety of Inhaled Corticosteroids. Am J Respir Crit Care Med 1998; Vol 157: pp. S1–S53
36. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332-336
37. Adcock IM, Maneechotesuwan K, Usmani O. Molecular interactions between glucocorticoids and long-acting beta2-agonists. J Allergy Clin Immunol 2002; 110: S261–268.
38. Barnes PJ Scientific rationale for inhaled combination therapy with long-acting b2-agonists and corticosteroids. Eur Respir J 2002; 19: 182–191
39. Ni Chroinin M, Greenstone IR, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD005307. DOI: 10.1002/14651858.CD005307
40. GINA Report, Global Strategy for Asthma Management and Prevention. Published November 2006. Доступна по адресу http://www.ginasthma.org
41. U.S. Food and Drug Administration. FDA Public Health Advisory. Serevent, Advair, Foradil. 2005. Доступно по адресу: www.fda.gov/cder/drug/advisory/LABA.htm
42. Salpeter SR, Buckley NS, Ormiston TM and Salpeter EE.Meta-Analysis: Effect of Long-Acting @b-Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths. Ann Intern Med. 2006;144:904-912.
43. FDA AERS database // www.fda.gov
44. National Heart, Lung, and Blood Institute. Guidelines for the Diagnosis and Management of Asthma. Update on Selected Topics 2002. Bethesda, MD: National Institutes of Health; 2002.
45. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000; 320:1368-73.
46. O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164:1392-7.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]